ArticleScientific reports2025
Elucidating a novel metabolic pathway for enhanced antimicrobial glycolipid biosurfactant production in the yeast Meyerozyma guilliermondii.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Overcoming Candida albicans biofilm drug resistance via azole-sophorolipid synergy.Scientific reports · 2026Article
- Yeasts associated with microalgal cultures in marine environments: ecological roles and biotechnological potential.FEMS yeast research · 2026Review
- Clearing Candida biofilms using combined antimicrobial sophorolipids with amphotericin B and itraconazole.FEMS yeast research · 2026Article
- A Glycolipid-Like Biosurfactant Molecule Derived From anInternational journal of microbiology · 2026Article
- Sophorolipids: multifunctional microbial glycolipids with diverse bioactivities and applications.Biotechnology for biofuels and bioproducts · 2025Review
- Yeast-derived glycolipids disrupt Candida biofilm and inhibit expression of genes in cell adhesion.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biosurfactants offer good advantages over synthetic counterparts, including biodegradability, environmentally friendly and low toxicity. This study employed a yeast Meyerozyma guilliermondii MX strain for bioconversion of lignocellulosic xylose and palm oil to valuable glycolipid biosurfactant with desirable properties. The objective was to elucidate metabolic pathways related to production of glycolipids and its functional properties. To enhance de novo glycolipid production, manipulation of responsible enzymatic genes was conducted using media and environmental means in comparison to the industrial glycolipid producer, Candida bombicola. Proteomic profiles of yeast cells grown with or without palm oil uncovered novel key metabolic enzymes, namely fatty acid biosynthetic enzymes, leading to formation of glycolipid precursors. qRT-PCR identified some cluster genes responsible for biosynthesis of desirable glycolipids. Finally, LC-MS-based lipidomics of glycolipid fraction identified 15-(2'-O-β-D-glucopyranosyl-β-D-glucopyranosyloxy)hexadecanoic acid 1',4″-lactone 6',6″-diacetate (663.4525 m/z) as a major product. Using co-carbon substrates in the presence of salt and zinc, maximum glycolipid yield was achieved (55.72 g/L) with 55.30% emulsification activity and 10 mg/L of CMCs. Mixed glycolipids demonstrated antibiofilm activity against Candida albicans shown by reduction of metabolic activity. The novel biosurfactant-producing yeast M. guilliermondii MX is a promising cell factory of new antibiofilm glycolipids with potential for industrial-scale up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.